Experimental Therapeutics
实验治疗学
基本信息
- 批准号:10600131
- 负责人:
- 金额:$ 3.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-07-14 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAchievementAgonistBasic ScienceBudgetsCancer Center Support GrantChemotherapy and/or radiationClinicalClinical InvestigatorClinical ResearchClinical TrialsCollaborationsComprehensive Cancer CenterDNA RepairDedicationsDevelopmentDirect CostsEndometrial CarcinomaEwings sarcomaFundingFunding MechanismsGoalsInstitutionInvestigational TherapiesJournalsLaboratoriesMalignant NeoplasmsManuscriptsMolecular TargetMonitorMultiple MyelomaPeer ReviewPharmacologic AscorbatePhasePhenotypePrivate SectorProductivityPublicationsRadiation therapyResearchResearch PersonnelResearch Project GrantsScientistTestingTherapeuticToll-like receptorsToxic effectToxicity due to chemotherapyTranslatingTranslational Researchbench to bedsidecancer cellcancer immunotherapycollegedrug developmenthigh throughput screeninginnovationinter-institutionalmembernanoparticlenew therapeutic targetnovelnovel therapeutic interventionpreclinical evaluationprogramsresponsesynthetic lethal interactiontranslational cancer researchtranslational scientist
项目摘要
PROJECT SUMMARY/ABSTRACT
Research in the Experimental Therapeutics (ET) program focuses on identification, development and testing of
new cancer therapeutics. This is accomplished through three overlapping specific aims centered on 1)
identifying potential targets and discovering therapeutics leads, 2) conducting preclinical evaluation of
promising new therapeutic approaches, and 3) evaluating innovative and promising agents, combinations, and
approaches to monitoring response in clinical trials. ET investigators are highly collaborative. Key scientific
achievements of ET investigators over the prior funding period include identification of novel therapeutic
targets in endometrial cancer and myeloma, nanoparticle based drug development, cancer immunotherapy
based on toll-like receptor (TLR9) agonists, use of pharmacologic ascorbate to enhance the efficacy and
reduce the toxicity of both chemotherapy and radiation therapy (in collaboration with the FRMI Program), and
expansion of investigator-initiated and Phase I capabilities including trials of intralesional therapy. There are 28
full and 16 associate members of ET including laboratory-based, translational and clinical investigators
spanning 13 departments across five colleges. Annual total peer-reviewed cancer direct costs in the most
recent budget year was $2.7 million ($1.9 million from the NCI). Additional funding included $3.8 million for
non-peer-reviewed research projects. ET members are highly collaborative having authored or co-authored
291 cancer-related peer-reviewed publications in the past five years, with 24% (n= 69) intraprogrammatic, 43%
(n= 124) interprogrammatic, and 42% (n= 123) interinstitutional publications. Twenty-nine manuscripts
appeared in high impact journals (Impact Factor ≥10).
项目摘要/摘要
实验治疗(ET)计划的研究重点是识别、开发和测试
新的癌症疗法。这是通过以1)为中心的三个重叠的具体目标来实现的
确定潜在靶点并发现治疗线索,2)进行临床前评估
有前景的新治疗方法,以及3)评估创新和有前景的药物、组合和
临床试验中监测反应的方法。ET调查人员高度合作。关键科学
ET研究人员在前一个资助期取得的成就包括发现新的治疗方法
子宫内膜癌和骨髓瘤的靶点,纳米药物开发,癌症免疫治疗
基于Toll样受体(TLR9)激动剂,使用药物抗坏血酸来增强疗效和
减少化疗和放射治疗的毒性(与fRMI方案合作),以及
扩大研究人员发起和第一阶段的能力,包括肿瘤内治疗的试验。有28个
ET的正式成员和16名准成员,包括实验室、翻译和临床研究人员
横跨五所学院的13个系。年度同行评审的癌症直接成本最高
最近的预算年度为270万美元(NCI为190万美元)。额外资金包括380万美元用于
未经同行评审的研究项目。ET成员具有高度的协作性,曾撰写或共同撰写
在过去五年中发表了291篇与癌症有关的同行评议出版物,其中24%(n=69)在方案内发表,43%
(n=124)跨计划出版物,42%(n=123)跨机构出版物。29篇稿件
出现在高影响力期刊上(影响系数≥10)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aliasger K Salem其他文献
Aliasger K Salem的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aliasger K Salem', 18)}}的其他基金
CST6-mRNA activated matrices for efficient bone regeneration
CST6-mRNA 激活基质可实现高效骨再生
- 批准号:
10576944 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
Cationic CAMKIIN nanoparticles that reduce chlorine-induced airway oxidative stress
阳离子 CAMKIIN 纳米颗粒可减少氯诱导的气道氧化应激
- 批准号:
10408405 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
CST6-mRNA activated matrices for efficient bone regeneration
CST6-mRNA 激活基质可实现高效骨再生
- 批准号:
10456455 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
Cationic CAMKIIN nanoparticles that reduce chlorine-induced airway oxidative stress
阳离子 CAMKIIN 纳米颗粒可减少氯诱导的气道氧化应激
- 批准号:
10698067 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
Engineered Optimal Adjuvant and Antigen Release from Biodegradable Nanoparticles
从可生物降解的纳米颗粒中释放优化的佐剂和抗原
- 批准号:
7742670 - 财政年份:2009
- 资助金额:
$ 3.39万 - 项目类别:
Engineered Optimal Adjuvant and Antigen Release from Biodegradable Nanoparticles
从可生物降解的纳米颗粒中释放优化的佐剂和抗原
- 批准号:
7586568 - 财政年份:2009
- 资助金额:
$ 3.39万 - 项目类别:
Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines
壳聚糖质粒 DNA 纳米复合物和腺病毒作为前列腺癌疫苗
- 批准号:
7568934 - 财政年份:2008
- 资助金额:
$ 3.39万 - 项目类别:
Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines
壳聚糖质粒 DNA 纳米复合物和腺病毒作为前列腺癌疫苗
- 批准号:
7452785 - 财政年份:2008
- 资助金额:
$ 3.39万 - 项目类别:
相似海外基金
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
- 批准号:
2335802 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
- 批准号:
2335801 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Standard Grant
A Longitudinal Study of the Relationship between Participation in a Comprehensive Exercise Program and Academic Achievement
参加综合锻炼计划与学业成绩之间关系的纵向研究
- 批准号:
24K14615 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Collaborative Research: Characterizing Best Practices of Instructors who Have Narrowed Performance Gaps in Undergraduate Student Achievement in Introductory STEM Courses
合作研究:缩小本科生 STEM 入门课程成绩差距的讲师的最佳实践
- 批准号:
2420369 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
- 批准号:
2335800 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Standard Grant
WTG: Diffusion of Research on Supporting Mathematics Achievement for Youth with Disabilities through Twitter Translational Visual Abstracts
WTG:通过 Twitter 翻译视觉摘要传播支持残疾青少年数学成就的研究
- 批准号:
2244734 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Standard Grant
The Impact of Emotional Experiences of Pride on Long-Term Goal Achievement Behaviors in Elite Athletes
骄傲的情感体验对优秀运动员长期目标实现行为的影响
- 批准号:
23K16740 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Meta-Analysis of the Instructional-Relational Model of Student Engagement and Math Achievement: A Moderation and Mediation Approach
学生参与度和数学成绩的教学关系模型的元分析:一种调节和中介方法
- 批准号:
2300738 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Standard Grant
Improving maths achievement in children with speech, language, and communication needs through 'collaborative vocabulary teaching'
通过“协作词汇教学”提高有言语、语言和交流需求的儿童的数学成绩
- 批准号:
2890475 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Studentship
HSI Institutional Transformation Project: Retention and Achievement for Introductory STEM English Learners (RAISE)
HSI 机构转型项目:STEM 英语入门学习者的保留和成就 (RAISE)
- 批准号:
2225178 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Continuing Grant